MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Suprefort Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Suprefort (Pancreas Cytomax A-1) is a natural Khavinson peptide bioregulator: a low-molecular-weight peptide complex ("complex A-1") extracted from animal pancreas and sold as a pancreas-supporting dietary supplement. The proposed mechanism is epigenetic and tissue-specific, short peptides that enter cells, interact with DNA and gene promoters, and modulate pancreatic gene expression [1][3]. Most molecular evidence actually comes from the synthetic analog tetrapeptide KEDW (Pancragen), which raises pancreatic differentiation genes such as PDX1 and PAX6 in cell culture [3][4]. In real-world use it is taken ORALLY as 10 mg capsules before meals; the subcutaneous figures on this page are an educational reconstitution reference only. The commonly cited dose is 1-2 capsules (10-20 mg) once or twice daily in 10-30 day courses repeated every 3-6 months. It is a dietary supplement, not an FDA- or EMA-approved drug, and is not a substitute for insulin or pancreatic enzyme therapy.
Reconstitute: Add 1 mL bacteriostatic water → 20 mg/mL concentration.
Typical dose: 10-20 mg/day orally (1-2 capsules)
Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg (200 mcg) on a U-100 insulin syringe.
Storage: Capsules: store at room temperature in a dry place protected from light and moisture. Educational reconstituted solution: refrigerate at 2-8 °C and use within ~4 weeks.
Half-life: Not formally characterized; orally dosed, with short circulating peptides cleared within minutes. Effect relies on a daily 10-30 day course rather than a single-dose half-life.
Route: Oral 10 mg capsules taken 30 minutes before meals. The subcutaneous reconstitution figures here are an educational measurement reference only.
Status: Dietary supplement / research use; NOT approved by the FDA or EMA as a drug. No large registered human RCTs of the finished product.
About Suprefort
Suprefort (Pancreas Cytomax A-1) is a natural peptide bioregulator developed within Professor Vladimir Khavinson's St. Petersburg "cytomax" tradition: short, organ-specific peptide complexes extracted from the pancreas of young animals and standardized as "peptide complex A-1" [1][2]. Clinically it is a dietary supplement taken ORALLY as 10 mg gelatin capsules before meals; the subcutaneous reconstitution figures on this page are an educational measurement reference only, not the real-world route.\n\nThe most commonly published Suprefort dosage is 1-2 capsules (10-20 mg of peptide complex A-1) once or twice daily, taken 30 minutes before meals, across a 10-30 day course that is repeated every 3-6 months [8]. A frequently cited daily serving is 2 capsules (20 mg), with intensive cycles running for up to 30 days and shorter 10-day maintenance cycles for people in good health.\n\nThis guide models a 20 mg vial reconstituted with 1.0 mL of bacteriostatic water (20 mg/mL) so the oral milligram figures map cleanly onto a U-100 insulin syringe: 10 mg ≈ 50 units (0.5 mL) and 20 mg ≈ 100 units (1.0 mL). These numbers exist only to make the dosing arithmetic concrete; Suprefort is not designed for injection.\n\nFrequency: Once or twice daily before meals, in 10-30 day courses repeated every 3-6 months. Suprefort is not FDA- or EMA-approved as a drug, and rigorous human trial data on the finished product are limited; this page is educational and not medical advice.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 1.0 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner wall of the 20 mg Suprefort vial; do not aim the stream at the powder, and avoid vigorous shaking.
Gently swirl or roll the vial until the solution is completely clear; the result is a 20 mg/mL concentration (200 mcg per insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the prescribed units per dose: 10 mg ≈ 50 units (0.5 mL); 20 mg ≈ 100 units (1.0 mL).
Educational note: Suprefort is clinically taken ORALLY as 10 mg capsules 30 minutes before meals — these subcutaneous reconstitution figures are a measurement reference only and are not a recommended delivery route for this supplement.
Interactive Suprefort Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 1 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 1mL water yields 20.00 mg/mL. To evaluate a 250mcg dose, pull to 1.3 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Days 1-10 — standard course (1 capsule, 10 mg of complex A-1) | 10000 mcg (10 mg) | 50 units (0.50 mL) |
| Days 11-30 — full/intensive course (2 capsules, 20 mg/day) | 20000 mcg (20 mg) | 100 units (1.00 mL) |
Administration guidelines: Refer to guidelines | 1 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Suprefort, 20 mg each):
- check8-week reference course at 20 mg/day ≈ 56 vials (1,120 mg) — note Suprefort is normally cycled in 10-30 day courses, not used continuously
- check12-week reference at 20 mg/day ≈ 84 vials (1,680 mg)
- check16-week reference at 20 mg/day ≈ 112 vials (2,240 mg)
- checkAt the 10 mg/day standard, halve these counts (e.g., 8 weeks ≈ 28 vials)
Insulin Syringes (U-100):
- checkOnce-daily dosing: 7 syringes per week
- check8 weeks ≈ 56 syringes; 12 weeks ≈ 84 syringes; 16 weeks ≈ 112 syringes
- checkBuy a margin for priming/wastage; note that in practice Suprefort is swallowed as a capsule, so no syringe is required
Bacteriostatic Water (30 mL bottles): Use 1 mL per vial for reconstitution.
- check8 weeks ≈ 56 mL ≈ 2 bottles
- check12 weeks ≈ 84 mL ≈ 3 bottles
- check16 weeks ≈ 112 mL ≈ 4 bottles
Alcohol Swabs:
- checkAbout 2 swabs per administration (vial top + injection site) in the educational model
- check8 weeks ≈ 112 swabs; 12 weeks ≈ 168 swabs; 16 weeks ≈ 224 swabs
- checkA 200-count box covers roughly a 12-week reference course
Mechanism of Action (MOA)
Suprefort belongs to Khavinson's "cytomax" family, peptide preparations obtained by extracting low-molecular-weight peptide fractions from the pancreas of young animals and standardizing them as "peptide complex A-1." The proposed mechanism is fundamentally different from conventional receptor pharmacology. Rather than binding a cell-surface receptor to trigger a signaling cascade, these short peptides are hypothesized to act as epigenetic, tissue-specific regulators: they penetrate the cell and its nucleus, interact with DNA and gene-promoter regions, and modulate the transcription of organ-specific genes, in this case pancreatic genes, restoring protein synthesis that declines with age [1][2][3].\n\nMost of the molecular and animal evidence behind this class comes not from the natural Suprefort complex itself but from its synthetic pancreatic analog, the tetrapeptide Lys-Glu-Asp-Trp (KEDW, marketed as "Pancragen") [6]. In cultured pancreatic cells, this peptide increases expression of master differentiation factors, including PDX1, PAX6, NGN3, FOXA2, NKX2.2 and PAX4, and promotes differentiation of insulin-, glucagon- and somatostatin-producing cells, particularly in models of cellular ageing [3][4][5]. The supporting cell-biology claim, that short Khavinson peptides actually enter the nucleus and bind DNA, was demonstrated directly with fluorescein-labeled peptides that localized to the cytoplasm, nucleus and nucleolus of human cells and bound deoxyribo-oligonucleotides in vitro [7].\n\nPharmacokinetics for Suprefort are not formally characterized in published Western literature, and this is an important honesty point. The product is taken by mouth, and the oral bioavailability of an animal-derived peptide complex, which is subject to gastric and intestinal proteolysis, is undefined. Short regulatory peptides that do reach the circulation are typically cleared within minutes, so there is no meaningful single-dose "half-life" in the way there is for a small-molecule drug. Instead, the bioregulator paradigm relies on repeated daily dosing over a 10-30 day course to produce cumulative, longer-lasting downstream effects on gene expression, with courses spaced every 3-6 months rather than taken continuously [1][2][8].\n\nThe real-world route is oral; the subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site, not a clinically validated or recommended delivery method for a dietary supplement. It is also worth stressing the evidence ceiling: the bulk of the literature is Russian, much of it in cell-culture or rodent/primate models or based on the synthetic analog rather than the finished Suprefort product, and independent international replication remains limited [2][3]. Suprefort is regulated as a dietary supplement, not as an approved pancreatic, antidiabetic or digestive medicine, and is not a substitute for insulin, pancreatic enzyme replacement, or any prescribed therapy [8].
Clinical Trial Efficacy Highlights
- starKhavinson's 2002 monograph 'Peptides and Ageing' (Neuroendocrinology Letters) consolidated more than two decades of work on organ-specific peptide preparations (cytomaxes/cytogens), proposing that low-molecular-weight peptide complexes such as the pancreatic complex A-1 in Suprefort act as informational regulators that restore age-impaired protein synthesis in their source tissue; it is a foundational narrative synthesis of largely Russian experimental data rather than a controlled clinical trial [1].
- starKhavinson and Anisimov (Bull Exp Biol Med, 2009) summarized 35 years of peptide-bioregulator research, reporting that long-term courses slowed age-related functional decline and, in rodent models, increased mean lifespan and reduced spontaneous tumor incidence; this body of work motivates the geroprotective framing of cytomax supplements like Suprefort but derives from animal and observational data, not human RCTs [2].
- starIn a systematic review of peptide regulation of gene expression (Molecules, 2021), Khavinson and colleagues catalogued how short peptides modulate transcription of tissue-specific genes, describing the pancreatic tetrapeptide KEDW, the synthetic analog of the natural A-1 complex, as upregulating pancreatic differentiation factors including PDX1, PAX6, NGN3 and FOXA2 in cell culture [3].
- starKhavinson et al. (Bull Exp Biol Med, 2013) reported that pancragen (Lys-Glu-Asp-Trp) promoted differentiation of cultured pancreatic cells during cellular ageing, raising expression of Ptf1a, Pdx1, Pax6, Foxa2, Nkx2.2 and Pax4, markers of functional islet and acinar maturation, in an in-vitro senescence model [4].
- starKhavinson et al. (Bull Exp Biol Med, 2012) demonstrated that organ-specific peptides stimulate cell differentiation in a tissue-specific manner during ageing, supporting the core claim that a pancreas-derived peptide complex preferentially influences pancreatic rather than unrelated tissues [5].
- starKhavinson et al. (Bull Exp Biol Med, 2010) characterized the biological activity of the endogenous pancreatic tetrapeptide Lys-Glu-Asp-Trp-NH2, the molecular basis for the synthetic pancreas bioregulator and a marker of the active fraction toward which natural complexes such as Suprefort are standardized [6].
- starFedoreyeva, Khavinson and colleagues (Biochemistry (Moscow), 2011) used fluorescein-labeled peptides to show that short Khavinson peptides penetrate the cytoplasm, nucleus and nucleolus of human (HeLa) cells and bind DNA and deoxyribo-oligonucleotides in vitro, providing experimental support for the proposed direct gene-regulatory mechanism, though with model peptides and a cell line rather than Suprefort itself [7].
- starEvidence limitation: there are no large, registered, peer-reviewed randomized controlled trials of the finished Suprefort product in humans; published dosing and indications come from the manufacturer (NPCRIZ / Peptide Bioregulators) and Russian clinical practice, so efficacy claims should be treated as preliminary and not established to Western regulatory standards [8].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningSuprefort is generally described as well tolerated in manufacturer and Russian-practice reports, but this reflects the absence of rigorous controlled safety data rather than proof of safety; the side-effect profile in humans is not well characterized [8].
- warningHypersensitivity/allergy is the most plausible adverse effect: the product is derived from animal (bovine) pancreatic tissue and capsules contain excipients such as lactose, gelatin, beetroot sugar, starch and Tween-80, any of which can trigger allergic or intolerance reactions.
- warningIt contains lactose, so people with lactose intolerance may experience digestive upset (bloating, cramping, diarrhea).
- warningAs an animal-tissue-derived product, it carries the general theoretical concerns of bovine-origin material; manufacturers state the source tissue is screened young livestock, but independent verification of sourcing and purity is limited.
- warningIt is NOT a substitute for prescribed therapy: people with diabetes, chronic pancreatitis, or pancreatic enzyme insufficiency should not replace insulin, antidiabetic drugs, or pancreatic enzyme replacement with Suprefort, and should not delay evidence-based treatment.
- warningSafety has not been established in pregnancy, breastfeeding, or children; these groups should avoid it unless supervised by a clinician.
- warningPharmacokinetics, drug interactions, and long-term effects are undefined; the subcutaneous reconstitution scheme on this page is an educational reference only and injecting a dietary supplement formulated for oral use is not advised.
- warningRegulatory/research status: Suprefort is sold as a dietary supplement and is NOT approved by the FDA or EMA as a drug for pancreatic, metabolic, or any other disease; treat all therapeutic claims as unproven.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Suprefort dosage?expand_more
The most commonly published Suprefort dosage is 1-2 capsules (10-20 mg of peptide complex A-1) taken once or twice daily, about 30 minutes before meals. A frequently cited daily serving is 2 capsules (20 mg). It is used in courses of roughly 10-30 days, repeated every 3-6 months rather than taken continuously. These figures come from the manufacturer and Russian practice, not from large controlled trials, and Suprefort is a dietary supplement, not a prescribed medicine, so dosing should be discussed with a qualified clinician.
Is Suprefort FDA approved?expand_more
No. Suprefort is not approved by the FDA or the EMA as a drug for any condition. It is sold as a dietary supplement (a Khavinson 'cytomax' peptide bioregulator), and there are no large registered randomized controlled trials of the finished product in humans. It is not a substitute for insulin, antidiabetic medication, or pancreatic enzyme replacement, and any disease-treatment claims should be regarded as unproven.
How is Suprefort taken, and what about reconstitution?expand_more
In real-world use Suprefort is taken ORALLY as 10 mg gelatin capsules before meals, so there is no genuine reconstitution step. The subcutaneous vial-and-bacteriostatic-water figures on this page are an educational measurement reference that mirrors how this site presents oral and topical compounds; they model a 20 mg vial in 1.0 mL of bacteriostatic water (20 mg/mL, so 10 mg ≈ 50 units and 20 mg ≈ 100 units) purely to make the dosing arithmetic concrete. Injecting a supplement formulated for oral use is not advised.
What is Suprefort's half-life and how long is a course?expand_more
Suprefort has no formally characterized half-life. It is an orally administered peptide complex with undefined bioavailability, and short regulatory peptides that reach the bloodstream are typically cleared within minutes, so there is no meaningful single-dose half-life as there would be for a small-molecule drug. The bioregulator approach instead relies on a daily course of about 10-30 days to build cumulative downstream effects, with courses repeated every 3-6 months.
Can Suprefort be stacked with other Khavinson peptide bioregulators?expand_more
In Khavinson 'cytomax' practice, organ-specific bioregulators are often cycled together (for example a pancreas complex alongside vascular, thymus, or pineal preparations) on the theory that each targets a different tissue. However, there are no rigorous interaction or combination studies for Suprefort, the evidence base is preliminary and largely Russian, and combining supplements increases the chance of allergic reactions and masks the source of any adverse effect. Anyone with diabetes or pancreatic disease should consult a clinician before stacking and should never replace prescribed therapy.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Suprefort, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Khavinson VKh, Anisimov VN. Peptide regulation of aging: 35-year research experience. Bull Exp Biol Med. 2009;148(1):94-98. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. View Scientific Paper →
Khavinson VKh, Durnova AO, Polyakova VO, et al. Effects of pancragen on the differentiation of pancreatic cells during their ageing. Bull Exp Biol Med. 2013;154(4):501-504. View Scientific Paper →
Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bull Exp Biol Med. 2012;153(1):148-151. View Scientific Paper →
Khavinson VKh, Gapparov MM, Sharanova NE, Vasilyev AV, Ryzhak GA. Study of biological activity of Lys-Glu-Asp-Trp-NH2 endogenous tetrapeptide. Bull Exp Biol Med. 2010;149(3):351-353. View Scientific Paper →
Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210-1219. View Scientific Paper →
Peptide Bioregulators / NPCRIZ. Suprefort (peptide complex A-1) natural pancreas peptide complex: composition, indications and administration (manufacturer product information). View Scientific Paper →